stockrowXenon Pharmaceuticals Inc.
XENE Healthcare Biotechnology
Xenon Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $7.5 million, down 20.5% from fiscal 2022.
- Revenue
- +100.7%
- EPS
- −3.74%
- Free cash flow
- −48.6%
Quarter to June 2026, against a year earlier
Follow XENE
Alert me
Xenon Pharmaceuticals Inc. (XENE) Revenue growth
Xenon Pharmaceuticals Inc.'s revenue growth over the twelve months to 31 March 2025 was −8.15%. Over the past ten years it has ranged from −88.4% (fiscal 2016) to 2,095.8% (fiscal 2019); the current reading is higher than 75% of that period. That is below the Biotechnology industry median of 6.26% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | −20.5% | 28.33 |
| FY2022 | −48.8% | (6.15) |
| FY2021 | −42.7% | (413.70) |
| FY2020 | 371.0% | (1,724.80) |
| FY2019 | 2,095.8% | 2,178.57 |
| FY2017 | −82.8% | 5.68 |
| FY2016 | −88.4% | (43.34) |
| FY2015 | −45.1% | — |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Mar 2025 | 100.7% | 199.08 |
| Sep 2022 | −98.4% | (22.55) |
| Jun 2022 | −75.8% | (176.98) |
| Mar 2022 | 101.2% | 128.59 |
| 22 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| ABCL AbCellera Biologics Inc. compare | 101.3% |
| IOVA Iovance Biotherapeutics, Inc. compare | 51.3% |
| TNGX Tango Therapeutics, Inc. compare | 48.3% |
| ACAD ACADIA Pharmaceuticals Inc. compare | 14.8% |
| XENE Xenon Pharmaceuticals Inc. | −8.15% |
| RLAY Relay Therapeutics, Inc. compare | −74.3% |
| VKTX Viking Therapeutics, Inc. compare | — |
| PBLS Parabilis Medicines, Inc. compare | — |
| IRON Disc Medicine, Inc. compare | — |
| Biotechnology industry median | 6.26% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on XENE
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Altman Z-score
- The full statement